LIPOSYN 20%
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Oct 1981
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 2h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LIPOSYN 20% is an injectable lipid emulsion approved in 1981 for parenteral nutrition support. The product delivers essential fatty acids and calories to patients unable to receive nutrition orally or enterally. It is a small-molecule lipid formulation administered intravenously as part of total parenteral nutrition (TPN) regimens.
LOE Approaching
As LOE approaches, the brand team is likely consolidating and focusing on cost-containment and retention strategies rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on LIPOSYN 20% offers limited career acceleration due to its LOE-approaching status and mature market position. Opportunities are best suited for professionals focused on operational excellence, payer relations, and lifecycle management rather than growth-oriented roles.
Account ManagerSupply Chain Specialist
Worked on LIPOSYN 20% at Abbott? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.